Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2845840 | 0.90 | HRH3 (0.72) | HRH3KDM4EGAAALDH1A1POLB | |
| SCHEMBL2848564 | 0.89 | HRH3 (0.58) | HRH3L3MBTL1POLB | |
| SCHEMBL2846600 | 0.87 | HRH3 (0.70) | HRH3KDM4EGAAALDH1A1POLB | |
| SCHEMBL2844182 | 0.85 | HRH3 (0.60) | HRH3GAAALDH1A1POLB | |
| SCHEMBL2841330 | 0.77 | HRH3 (1.00) | HRH3L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL2844224 | 0.75 | HRH3 (0.93) | HRH3L3MBTL1KDM4EALDH1A1POLB | |
| SCHEMBL7896454 | 0.75 | POLB (0.50) | HRH3L3MBTL1ALDH1A1POLBNPC1 | |
| SCHEMBL2851722 | 0.75 | HRH3 (0.95) | HRH3KDM4EALDH1A1 | |
| SCHEMBL600450 | 0.75 | LMNA (0.62) | HRH3L3MBTL1KDM4EGAAALDH1A1 | |
| SCHEMBL2851223 | 0.74 | HRH3 (0.76) | HRH3L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010062245-A1 | SPIROCYCLOBUTYL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | WO | claimed |
| US-20100130477-A1 | Spirocyclobutyl Piperidine Derivatives | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | claimed |
| WO-2010062245-A1 | SPIROCYCLOBUTYL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | WO | disclosed |
| US-20100130477-A1 | Spirocyclobutyl Piperidine Derivatives | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
| US-20100130477-A1 | Spirocyclobutyl Piperidine Derivatives | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
| US-20100130477-A1 | Spirocyclobutyl Piperidine Derivatives | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130477-A1 | Spirocyclobutyl Piperidine Derivatives | HRH3, HRH4, HRH2 | HRH3 1/4885L3MBTL1 4754/4885KDM4E 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.